• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
J Clin Invest. Mar 1994; 93(3): 1288–1292.
PMCID: PMC294082

Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease.

Abstract

Gaucher disease (GD; glucosylceramidosis) is caused by a deficient activity of the enzyme glucocerebrosidase (GC). Clinical manifestations are highly variable and cannot be predicted accurately on the basis of the properties of mutant GC. Analysis of secondary abnormalities, such as elevated plasma levels of some hydrolases, may help to increase insight into the complicated pathophysiology of the disease and could also provide useful disease markers. The recent availability of enzyme supplementation therapy for GD increases the need for markers as early predictors of the efficacy of treatment. We report the finding of a very marked increase in chitotrisidase activity in plasma of 30 of 32 symptomatic type 1 GD patients studied: the median activity being > 600 times the median value in plasma of healthy volunteers. In three GC-deficient individuals without clinical symptoms, only slight increases were noted. Chitotriosidase activity was absent in plasma of three control subjects and two patients. During enzyme supplementation therapy, chitotriosidase activity declined dramatically. We conclude that plasma chitotriosidase levels can serve as a new diagnostic hallmark of GD and should prove to be useful in assessing whether clinical manifestations of GD are present and for monitoring the efficacy of therapeutic intervention.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (803K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Van Weely S, Van Leeuwen MB, Jansen ID, De Bruijn MA, Brouwer-Kelder EM, Schram AW, Sa Miranda MC, Barranger JA, Petersen EM, Goldblatt J, et al. Clinical phenotype of Gaucher disease in relation to properties of mutant glucocerebrosidase in cultured fibroblasts. Biochim Biophys Acta. 1991 Jun 5;1096(4):301–311. [PubMed]
  • Beutler E, Gelbart T, Kuhl W, Zimran A, West C. Mutations in Jewish patients with Gaucher disease. Blood. 1992 Apr 1;79(7):1662–1666. [PubMed]
  • Sidransky E, Tsuji S, Martin BM, Stubblefield B, Ginns EI. DNA mutation analysis of Gaucher patients. Am J Med Genet. 1992 Feb 1;42(3):331–336. [PubMed]
  • Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, Mankin HJ, Murray GJ, Parker RI, Argoff CE, et al. Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med. 1991 May 23;324(21):1464–1470. [PubMed]
  • Beutler E, Kay A, Saven A, Garver P, Thurston D, Dawson A, Rosenbloom B. Enzyme replacement therapy for Gaucher disease. Blood. 1991 Sep 1;78(5):1183–1189. [PubMed]
  • Daniels LB, Glew RH. beta-Glucosidase assays in the diagnosis of Gaucher's disease. Clin Chem. 1982 Apr;28(4 Pt 1):569–577. [PubMed]
  • Aerts JM, Donker-Koopman WE, Koot M, Barranger JA, Tager JM, Schram AW. Deficient activity of glucocerebrosidase in urine from patients with type 1 Gaucher disease. Clin Chim Acta. 1986 Jul 30;158(2):155–163. [PubMed]
  • Zimran A, Kay A, Gelbart T, Garver P, Thurston D, Saven A, Beutler E. Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients. Medicine (Baltimore) 1992 Nov;71(6):337–353. [PubMed]
  • Mörsky P. Turbidimetric determination of lysozyme with Micrococcus lysodeikticus cells: reexamination of reaction conditions. Anal Biochem. 1983 Jan;128(1):77–85. [PubMed]
  • Chambers JP, Aquino L, Glew RH, Lee RE, McCafferty LR. Determination of serum acid phosphatase in Gaucher's disease using 4-methylumbelliferyl phosphate. Clin Chim Acta. 1977 Oct 1;80(1):67–77. [PubMed]
  • Yang Y, Hamaguchi K. Hydrolysis of 4-methylumbelliferyl N-acetyl-chitotetraoside catalyzed by hen lysozyme. J Biochem. 1980 Sep;88(3):829–836. [PubMed]
  • Moss DW. Changes in enzyme expression related to differentiation and regulatory factors: the acid phosphatase of osteoclasts and other macrophages. Clin Chim Acta. 1992 Jul 31;209(1-2):131–138. [PubMed]
  • Hollak CE, Aerts JM, van Oers MH. Treatment of Gaucher's disease. N Engl J Med. 1993 May 27;328(21):1565–1567. [PubMed]
  • Den Tandt WR, Inaba T, Verhamme I, Overdyk B, Brouwer J, Prieur D. Non-identity of human plasma lysozyme and 4-methylumbelliferyl-tetra-N-acetyl-beta-D-chitotetraoside hydrolase. Int J Biochem. 1988;20(7):713–719. [PubMed]
  • TUCHMAN LR, SUNA H, CARR JJ. Elevation of serum acid phosphatase in Gaucher's disease. J Mt Sinai Hosp N Y. 1956 Mar-Apr;23(2):227–229. [PubMed]
  • CROCKER AC, LANDING BH. Phosphatase studies in Gaucher's disease. Metabolism. 1960 Apr;9:341–362. [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • Cited in Books
    Cited in Books
    PubMed Central articles cited in books
  • Compound
    Compound
    PubChem Compound links
  • MedGen
    MedGen
    Related information in MedGen
  • OMIM
    OMIM
    OMIM record citing PubMed
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...